These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36789991)

  • 1. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults.
    Tomaszewska-Kiecana M; Dryja A; Ullmann M; Petit-Frere C; Illes A; Dagres C; Monnet J
    Expert Rev Clin Immunol; 2023 Apr; 19(4):447-455. PubMed ID: 36789991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults.
    Tomaszewska-Kiecana M; Ullmann M; Petit-Frere C; Monnet J; Dagres C; Illes A
    Expert Rev Clin Immunol; 2023 Apr; 19(4):439-446. PubMed ID: 36715299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.
    Yu KS; Ryu H; Shin D; Park M; Hwang J; Moon SJ; Kim MG; Keystone E; Smolen JS; Kim S; Bae Y; Jeon D; Jang J; Yang G; Bae J; Lee J; Burmester GR
    Expert Opin Biol Ther; 2024 Jul; 24(7):681-689. PubMed ID: 38905143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
    Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
    Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2023 Nov; 40(11):4889-4906. PubMed ID: 37707674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants.
    Tang H; Civoli F; Tatarewicz S; Vandenkoornhuyse N; Finck B
    Adv Ther; 2024 Mar; 41(3):991-1009. PubMed ID: 38180721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector.
    Fettner S; Mela C; Wildenhahn F; Tavanti M; Wells C; Douglass W; Mallalieu NL
    Expert Opin Drug Deliv; 2019 May; 16(5):551-561. PubMed ID: 31043095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects.
    Bush J; Kawakami K; Muniz R
    BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparable Pharmacokinetics, Safety, and Tolerability of Etrolizumab Administered by Prefilled Syringe or Autoinjector in a Randomized Trial in Healthy Volunteers.
    Zhang W; Tyrrell H; Ding HT; Pulley J; Boruvka A; Erickson R; Abouhossein M; Ravanello R; Tang MT
    Adv Ther; 2021 May; 38(5):2418-2434. PubMed ID: 33778929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects.
    Shin D; Lee Y; Jeong D; Ellis-Pegler R
    Drug Des Devel Ther; 2018; 12():3799-3805. PubMed ID: 30464411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence Between a New Omalizumab Prefilled Syringe With an Autoinjector or with a Needle Safety Device Compared with the Current Prefilled Syringe: A Randomized Controlled Trial in Healthy Volunteers.
    Sangana R; Xu Y; Shah B; Tian X; Zack J; Shakeri-Nejad K; Kalluri S; Jones I; Ligueros-Saylan M; Taylor AF; Jain DK; Scosyrev E; Uddin A; Laurent N; Paganoni P
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):611-620. PubMed ID: 38389387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tezepelumab Pharmacokinetics, Safety, and Tolerability After Administration via Vial-and-syringe, Accessorized Prefilled Syringe, or Autoinjector: A Randomized Trial in Healthy Volunteers.
    Zheng Y; Abuqayyas L; Megally A; Fuhr R; Sałapa K; Downie J; Colice G
    Clin Ther; 2021 Jan; 43(1):142-155.e5. PubMed ID: 33380362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GP2015, a proposed etanercept biosimilar: Pharmacokinetic similarity to its reference product and comparison of its autoinjector device with prefilled syringes.
    von Richter O; Skerjanec A; Afonso M; Sanguino Heinrich S; Poetzl J; Woehling H; Velinova M; Koch A; Kollins D; Macke L; Wuerth G
    Br J Clin Pharmacol; 2017 Apr; 83(4):732-741. PubMed ID: 27790726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic Comparability of Risankizumab Formulations in Prefilled Syringe and Auto-injector for Subcutaneous Injection.
    Lon HK; Cheng L; Nudurupati S; Loebbert R; Duan R; Kalabic J; Pang Y
    Clin Ther; 2021 Mar; 43(3):629-636. PubMed ID: 33549311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects.
    Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J
    Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe.
    Cohen YZ; Zhang X; Xia B; Kosloski MP; Kamal MA; Davis JD; Kanamaluru V; Xu C
    Clin Pharmacol Drug Dev; 2022 May; 11(5):675-681. PubMed ID: 35278283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised, phase I pharmacokinetic study of adalimumab biosimilar CT-P17 (40 mg/0.4 mL) by autoinjector and prefilled syringe in healthy subjects.
    Davidson A; Brimhall D; Kay J; Keystone E; Lee SJ; Kim SH; Bae YJ; Choi EJ; Furst DE
    Br J Clin Pharmacol; 2021 Nov; 87(11):4323-4333. PubMed ID: 33822406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Pharmacokinetics, Safety, and Tolerability of the Autoinjector (AI) and Pre-Filled Syringe (PFS) of SB4 in Healthy Subjects.
    Shin D; Kim Y; Go A; Velinova M
    Drug Des Devel Ther; 2020; 14():43-50. PubMed ID: 32021090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
    Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
    Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pharmacokinetic Bioequivalence Study of Fremanezumab Administered Subcutaneously Using an Autoinjector and a Prefilled Syringe.
    Cherniakov I; Cohen-Barak O; Tiver R; Gillespie M; Kessler Y; Gutierrez M; Rasamoelisolo M; Li S; Shen H; Hallak H; Loupe PS; Smith M; Rabinovich-Guilatt L; Spiegelstein O
    Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1018-1027. PubMed ID: 33411992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.